NATCO Pharma Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 6/6
NATCO Pharma yıllık ortalama 33.3% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.3% annual. Gelirler growing yılda ortalama 19.1% oranında artmaktadır. NATCO Pharma'in özkaynak karlılığı 27.2% ve net marjı 42.6%'dir.
Anahtar bilgiler
33.3%
Kazanç büyüme oranı
33.7%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 17.5% |
| Gelir büyüme oranı | 19.1% |
| Özkaynak getirisi | 27.2% |
| Net Marj | 42.6% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18
Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 15We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02Gelir ve Gider Dağılımı
NATCO Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 45,638 | 19,448 | 5,689 | 0 |
| 30 Jun 24 | 43,490 | 16,365 | 5,288 | 0 |
| 31 Mar 24 | 40,020 | 13,883 | 5,360 | 0 |
| 31 Dec 23 | 38,298 | 12,778 | 5,537 | 0 |
| 30 Sep 23 | 35,637 | 11,274 | 5,665 | 0 |
| 30 Jun 23 | 29,630 | 8,152 | 4,730 | 0 |
| 31 Mar 23 | 27,085 | 7,153 | 4,733 | 0 |
| 31 Dec 22 | 24,074 | 3,890 | 5,037 | 0 |
| 30 Sep 22 | 24,754 | 4,071 | 5,163 | 0 |
| 30 Jun 22 | 24,191 | 4,154 | 4,595 | 0 |
| 31 Mar 22 | 19,462 | 1,700 | 5,005 | 0 |
| 31 Dec 21 | 16,833 | 2,735 | 4,659 | 0 |
| 30 Sep 21 | 14,780 | 2,558 | 4,491 | 0 |
| 30 Jun 21 | 18,990 | 3,931 | 4,278 | 0 |
| 31 Mar 21 | 20,561 | 4,409 | 4,507 | 0 |
| 31 Dec 20 | 21,756 | 4,820 | 5,043 | 0 |
| 30 Sep 20 | 23,026 | 5,238 | 5,007 | 0 |
| 30 Jun 20 | 19,861 | 4,404 | 3,770 | 0 |
| 31 Mar 20 | 19,150 | 4,608 | 4,774 | 0 |
| 31 Dec 19 | 19,159 | 4,875 | 3,807 | 0 |
| 30 Sep 19 | 19,904 | 5,425 | 3,762 | 0 |
| 30 Jun 19 | 20,482 | 6,060 | 3,664 | 0 |
| 31 Mar 19 | 20,945 | 6,444 | 4,466 | 0 |
| 31 Dec 18 | 24,066 | 8,235 | 4,008 | 0 |
| 30 Sep 18 | 24,121 | 8,815 | 3,863 | 0 |
| 30 Jun 18 | 22,953 | 7,838 | 3,512 | 0 |
| 31 Mar 18 | 21,848 | 6,962 | 3,422 | 0 |
| 31 Dec 17 | 19,817 | 5,730 | 3,124 | 0 |
| 30 Sep 17 | 20,895 | 5,506 | 2,975 | 0 |
| 30 Jun 17 | 21,679 | 5,323 | 2,546 | 0 |
| 31 Mar 17 | 20,202 | 4,860 | 2,698 | 0 |
| 31 Dec 16 | 17,697 | 3,680 | 2,071 | 0 |
| 30 Sep 16 | 13,692 | 2,113 | 2,187 | 0 |
| 30 Jun 16 | 12,431 | 1,748 | 1,960 | 0 |
| 31 Mar 16 | 10,423 | 1,549 | 1,918 | 0 |
| 31 Dec 15 | 9,355 | 1,494 | 2,569 | 126 |
| 30 Sep 15 | 8,549 | 1,266 | 2,432 | 126 |
| 30 Jun 15 | 8,390 | 1,294 | 1,454 | 0 |
| 31 Mar 15 | 7,305 | 1,293 | 1,276 | 0 |
| 31 Dec 14 | 8,089 | 1,042 | 2,013 | 143 |
| 30 Sep 14 | 8,108 | 1,199 | 1,977 | 143 |
| 30 Jun 14 | 7,648 | 1,144 | 1,187 | 0 |
| 31 Mar 14 | 7,389 | 1,027 | 1,847 | 143 |
| 31 Dec 13 | 7,078 | 900 | 1,520 | 146 |
Kaliteli Kazançlar: NATCOPHARM yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: NATCOPHARM 'nin mevcut net kar marjları (42.6%) geçen yılın (31.6%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: NATCOPHARM şirketinin kazançları son 5 yılda yılda 33.3% oranında önemli ölçüde arttı.
Büyüme Hızlandırma: NATCOPHARM 'un son bir yıldaki kazanç büyümesi ( 72.5% ) 5 yıllık ortalamasını (yıllık 33.3% ) aşıyor.
Kazançlar vs. Sektör: NATCOPHARM geçen yılki kazanç büyümesi ( 72.5% ) Pharmaceuticals sektörünün 20.5% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: NATCOPHARM 'nin Özsermaye Getirisi ( 27.2% ) yüksek olarak değerlendiriliyor.